Loopholes, Lack Of Staffing Stymie Transparency Of Oregon’s Drug Pricing Program

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

The state’s Prescription Drug Price Transparency Program was created to illuminate pharmaceutical pricing practices, but pharmaceutical companies have shielded information they say infringes on trade secrets.

Revision of PBM Law Sails Through House Without Opposition

HB 2388 makes a previous law regulating PBMs more effective and gives state regulators the ability to police bad actors who violate the law.

The House unanimously passed legislation Wednesday morning to better regulate pharmacy benefit managers, giving enforcement powers to the Oregon Department of Consumer & Business Services, designed to ensure the PBMs act lawfully and treat pharmacists fairly.

Pharmacists on Track to Win Better Protection from PBM Abuses

House Bill 2388 will strengthen the existing regulation of pharmacy benefit managers by giving the Department of Consumer & Business Services the ability to investigate complaints and cancel a company’s registration if the PBM commits fraud or fails to pay civil penalties.

Pharmacists appear poised to add significant teeth to the state law regulating pharmacy benefit managers, persuading the Legislature to make the first changes to the law since it was enacted in 2013.

Nosse and Steiner Hayward Back Mandatory Rebates for High-Cost Drugs

The Oregon Department of Consumer and Business Services would step in if a drug exceeded $10,000 or had cost increases greater than 3.4 percent. State regulators would index a price according to what other countries have negotiated for the drugs. Consumers would also see a cap on costs that they pay out-of-pocket.

Rep. Rob Nosse, D-Portland, touted his aggressive and innovative approach to tackling uncontrolled pharmaceutical costs on Thursday, calling on Oregon to lead where Congress has failed and other state-based reforms have fallen short.

Subscribe to pharmaceutical